BioSpace News Archive

Pascal Biosciences Inc. is pleased to announce that its common shares were accepted for listing on the Frankfurt Stock Exchange under the trading symbol | ISIN: CA7024781089 | WKN: A2DQU4.

Biosight Ltd. announced that that the U.S. Food and Drug Administration has granted Fast Track designation for BST-236 for the treatment of acute myeloid leukemia in adults who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Richard Murray, Ph.D., chief executive officer and president of Jounce Therapeutics,will participate in a fireside chat at the BTIG Virtual Biotechnology Conference 2020 on Tuesday, August 11, 2020 at 2:00 PM ET. A live webcast of the presentation will be

IGM Biosciences, Inc., a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, announced that Fred Schwarzer, Chief Executive Officer, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11 at 1:45 p.m. ET.

Amicus Therapeutics announced that members of the Amicus senior leadership team will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August 11, 2020 at 9:00 a.m. E.T.

Oxford Immunotec Global PLC, a global diagnostics company, announced second quarter 2020 financial results.

Arvinas, Inc., a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, reported financial results for the second quarter ended June 30, 2020 and provided a corporate update.

MediPharm Labs Corp. a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce the appointment of Chris Halyk – former President of Janssen Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson – to its Board of Directors, effective immediately.

T-Cure Bioscience, Inc. announced that the Company has extended its ongoing research collaboration with the National Heart Lung and Blood Institute, through a formal Collaborative Research and Development Agreement to advance the Company’s HERV-E targeting TCR therapy for renal cell cancer.

Total product and royalty revenues of $593 million (+16% vs Q2 2019) for the quarter ended June 30, 2020; Jakafi® (ruxolitinib) revenues of $474 million in Q2 2020 (+16% vs Q2 2019)